Vault-13

Paradigm Biocapital Advisors LP

NEW YORK, NY · CIK 1855655 · 13F filing filed 2022-05-16

SEC-registered investment adviser since 2021 · limited partnership

As an employer

$378.2m reported value +8.0% vs Q4 2021
25positions
65.2%in top 10
7 new 16 added 2 reduced 6 sold out vs Q4 2021

Holdings, Q1 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 ASCENDIS PHARMA A/S SPONSORED ADR SPONSORED ADR 321,621 $37.7m9.98% 9.98% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 218.2k, Q1 2022 321.6k +103.5k +103,463 47.4%
2 GLOBAL BLOOD THERAPEUTICS IN COM GBT GBT 966,827 $33.5m8.86% 8.86% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 780.5k, Q1 2022 966.8k +186.3k +186,347 23.9%
3 ARVINAS INC COM ARVN ARVN 491,333 $33.1m8.74% 8.74% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 268.5k, Q1 2022 491.3k +222.8k +222,814 83.0%
4 LEGEND BIOTECH CORP SPONSORED ADS LEGN LEGN 831,728 $30.2m7.99% 7.99% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 386.0k, Q1 2022 831.7k +445.8k +445,761 115.5%
5 SIERRA ONCOLOGY INC COM NEW COM NEW 771,314 $24.7m6.54% 6.54% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 474.9k, Q1 2022 771.3k +296.4k +296,369 62.4%
6 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 1,256,051 $23.2m6.14% 6.14% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 1.2m, Q1 2022 1.3m +47.0k +47,000 3.9%
7 INCYTE CORP COM INCY INCY 234,419 $18.6m4.92% 4.92% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 234.4k
8 IVERIC BIO INC COM OPHT OPHT 910,416 $15.3m4.05% 4.05% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 815.6k, Q1 2022 910.4k +94.8k +94,835 11.6%
9 IOVANCE BIOTHERAPEUTICS INC COM IOVA IOVA 907,428 $15.1m4.00% 4.00% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 844.0k, Q1 2022 907.4k +63.4k +63,423 7.5%
10 IMMUNOCORE HLDGS PLC ADS IMCR IMCR 499,190 $14.9m3.95% 3.95% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 134.2k, Q1 2022 499.2k +364.9k +364,941 271.8%
11 HORIZON THERAPEUTICS PUB L SHS HZNP HZNP 136,243 $14.3m3.79% 3.79% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 136.2k
12 UNITED THERAPEUTICS CORP DEL COM UTHR UTHR 75,635 $13.6m3.59% 3.59% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 75.6k
13 ZENTALIS PHARMACEUTICALS INC COM ZNTL ZNTL 287,577 $13.3m3.51% 3.51% ReducedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 300.4k, Q1 2022 287.6k -12.9k -12,857 -4.3%
14 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 701,356 $12.2m3.22% 3.22% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 453.1k, Q1 2022 701.4k +248.3k +248,265 54.8%
15 C4 THERAPEUTICS INC COM STK CCCC CCCC 499,496 $12.1m3.20% 3.20% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 258.7k, Q1 2022 499.5k +240.8k +240,750 93.0%
16 OYSTER PT PHARMA INC COM OYST OYST 987,698 $11.5m3.04% 3.04% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 304.2k, Q1 2022 987.7k +683.5k +683,460 224.7%
17 PROTHENA CORP PLC SHS PRTA PRTA 267,946 $9.8m2.59% 2.59% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 267.9k
18 KYMERA THERAPEUTICS INC COM KYMR KYMR 227,034 $9.6m2.54% 2.54% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 125.9k, Q1 2022 227.0k +101.2k +101,176 80.4%
19 MIRATI THERAPEUTICS INC COM MRTX MRTX 98,383 $8.1m2.14% 2.14% ReducedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 260.1k, Q1 2022 98.4k -161.7k -161,732 -62.2%
20 MERUS N V COM MRUS MRUS 249,738 $6.6m1.75% 1.75% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 249.7k
21 VOR BIOPHARMA INC COM COM 894,404 $5.4m1.43% 1.43% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 629.3k, Q1 2022 894.4k +265.1k +265,062 42.1%
22 ESPERION THERAPEUTICS INC NE COM ESPR ESPR 1,157,246 $5.4m1.42% 1.42% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 839.3k, Q1 2022 1.2m +318.0k +317,989 37.9%
23 FULCRUM THERAPEUTICS INC COM FULC FULC 212,961 $5.0m1.33% 1.33% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 213.0k
24 ALPINE IMMUNE SCIENCES INC COM NVLS NVLS 336,229 $3.0m0.80% 0.80% NewShares held: Q2 2021 —, Q3 2021 —, Q4 2021 0, Q1 2022 336.2k
25 GRACELL BIOTECHNOLOGIES INC SPONSORED ADS SPONSORED ADS 783,445 $1.8m0.48% 0.48% AddedShares held: Q2 2021 —, Q3 2021 —, Q4 2021 545.4k, Q1 2022 783.4k +238.1k +238,057 43.6%

Sold out since Q4 2021

SecurityTickerShares held beforeValue then
ARENA PHARMACEUTICALS INC ARNA ARNA 251,777 $23.4m251.8k shares
SEAGEN INC SGEN SGEN 100,687 $15.6m100.7k shares
ARGENX SE ARGX ARGX 42,050 $14.7m42.0k shares
INSMED INC INSM INSM 394,358 $10.7m394.4k shares
GALAPAGOS NV LKFT LKFT 167,824 $9.3m167.8k shares
ENANTA PHARMACEUTICALS INC ENTA ENTA 75,507 $5.6m75.5k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
OLEMA PHARMACEUTICALS INC OLMA · 13G · filed 2025-02-14 OLMA 10.0%≈ $92.9m 13G 2025-02-14
EDGEWISE THERAPEUTICS INC EWTX · 13G · filed 2026-08-14 EWTX 9.5%≈ $415.1m +3.3 pts 13G 2026-08-14
ACHIEVE LIFE SCIENCES INC ACHV · 13G · filed 2026-04-24 ACHV 9.2%≈ $64.7m new 13G 2026-04-24
ASSEMBLY BIOSCIENCES INC ASMB · 13G · filed 2026-08-14 ASMB 7.8%≈ $42.7m +2.4 pts 13G 2026-08-14
VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 VRDN 6.1%≈ $123.5m +1.0 pts 13G 2026-08-14
TYRA BIOSCIENCES INC TYRA · 13G · filed 2026-09-17 TYRA 5.8%≈ $110.9m new 13G 2026-09-17
LEXEO THERAPEUTICS INC LXEO · 13G · filed 2026-08-14 LXEO 5.3%≈ $19.4m -3.0 pts 13G 2026-08-14
MBX BIOSCIENCES INC MBX · 13G · filed 2026-06-24 MBX 5.2%≈ $137.6m new 13G 2026-06-24
SPYRE THERAPEUTICS INC SYRE · 13G · filed 2026-10-01 SYRE 5.1%≈ $395.7m new 13G 2026-10-01
JADE BIOSCIENCES INC JBIO · 13G · filed 2026-07-17 JBIO 5.1%≈ $69.0m new 13G 2026-07-17